You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 4, 2025

Details for Patent: 10,143,656


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,143,656 protect, and when does it expire?

Patent 10,143,656 protects SUTAB and is included in one NDA.

Summary for Patent: 10,143,656
Title:Solid oral sulfate salt formulations for cleaning a colon and methods of using same
Abstract: Disclosed herein are solid oral dosage formulations comprising sodium sulfate, magnesium sulfate, and potassium chloride for inducing purgation of the colon of a subject. Furthermore, the disclosed compositions and formulations are useful to cleanse the colon when administered in sufficient quantities. Methods for inducing purgation of the colon and for cleansing the colon are also disclosed.
Inventor(s): Cleveland; Mark vB. (Norwell, MA), Dennett, Jr.; Edmund V. (Walpole, MA), Pelham; Russell W. (Duxbury, MA)
Assignee:
Application Number:15/669,749
Patent Claim Types:
see list of patent claims
Formulation; Dosage form;
Patent landscape, scope, and claims:

United States Patent 10,143,656: A Comprehensive Analysis

Introduction

United States Patent 10,143,656, titled "Solid oral sulfate salt formulations for cleaning a colon and methods of using same," is a significant patent in the field of gastrointestinal cleansing. This patent, issued on December 4, 2018, is held by Braintree Laboratories, Inc., and it plays a crucial role in the development and use of colon cleansing formulations.

Inventors and Assignees

The patent was invented by Mark vB. Cleveland, Edmund V. Dennett, Jr., and Russell W. Pelham, all associated with Braintree Laboratories, Inc., based in Braintree, Massachusetts[2][4].

Patent Claims and Scope

The patent claims cover solid oral dosage formulations that include sodium sulfate, magnesium sulfate, and potassium chloride. These formulations are designed to induce purgation of the colon, making them essential for bowel cleansing prior to procedures such as colonoscopy or barium enema X-ray examinations.

Key Components

  • Sodium Sulfate: The primary active ingredient responsible for inducing purgation.
  • Magnesium Sulfate: Another sulfate salt that aids in the cleansing process.
  • Potassium Chloride: Included to help maintain electrolyte balance during the cleansing process[2][4].

Methods of Use

The patent not only describes the composition of the formulations but also outlines the methods for inducing purgation and cleansing the colon. These methods involve administering the formulations in sufficient quantities to ensure effective bowel cleansing[2][4].

Patent Expiration Dates

The patent is set to expire on August 4, 2037. This expiration date is crucial as it determines the period during which Braintree Laboratories, Inc. holds exclusive rights to the formulation and methods described in the patent[2][4].

Related Patents

There are several related patents that extend the scope and protection of the original patent. These include:

  • US Patent 11,033,498: Issued on June 15, 2021, with the same inventors and assignee, covering similar formulations and methods.
  • US Patent 11,382,864 and US Patent 11,638,697: Also set to expire on August 4, 2037, these patents further solidify the intellectual property rights of Braintree Laboratories, Inc. in this area[2][4].

Drug Patent and Exclusivity

The patent assigns exclusive legal rights to Braintree Laboratories, Inc., protecting the proprietary chemical formulation. This exclusivity is crucial for the commercialization strategy of the company, as it prevents other entities from manufacturing or marketing similar products during the patent period. The FDA also grants exclusivity periods that can run concurrently with the patent, ensuring sole marketing rights for the approved drug[2][3].

Impact on the Pharmaceutical Industry

The patent landscape, particularly in the pharmaceutical and biotechnology industries, is heavily influenced by the scope and claims of patents like US 10,143,656. The Federal Circuit's stance on genus claims, as discussed in legal analyses, highlights the challenges innovators face in obtaining and maintaining meaningful patent protection. Broad claims can be invalidated if they do not meet the written description and enablement requirements, while narrow claims can be easily circumvented by competitors[3].

Economic and Market Implications

The market for gastrointestinal cleansing products is significant, and patents like US 10,143,656 play a critical role in protecting the investments made by companies like Braintree Laboratories, Inc. The absence of generic versions, as indicated by the lack of a therapeutically equivalent version of Sutab, further underscores the economic importance of these patents[2].

Legal and Regulatory Considerations

The patent claims must adhere to the statutory requirements outlined in 35 U.S.C. § 112(a), which includes the written description and enablement requirements. The Federal Circuit's rigid position on these requirements can make it challenging for innovators to secure broad patent protection without risking invalidation[3].

Conclusion

United States Patent 10,143,656 is a pivotal patent in the field of colon cleansing formulations. It protects the proprietary formulations and methods developed by Braintree Laboratories, Inc., ensuring exclusive rights until its expiration in 2037. The patent's scope and claims are critical in the pharmaceutical industry, influencing both the commercialization strategies of companies and the broader legal landscape surrounding patent protection.

Key Takeaways

  • Patent Scope: Covers solid oral dosage formulations including sodium sulfate, magnesium sulfate, and potassium chloride.
  • Methods of Use: Describes methods for inducing purgation and cleansing the colon.
  • Expiration Date: August 4, 2037.
  • Related Patents: Includes US Patents 11,033,498, 11,382,864, and 11,638,697.
  • Impact on Industry: Significant for protecting investments and influencing commercialization strategies.
  • Legal Considerations: Must adhere to 35 U.S.C. § 112(a) requirements.

Frequently Asked Questions

Q: What is the primary use of the formulations described in US Patent 10,143,656? A: The primary use is for bowel cleansing prior to procedures such as colonoscopy or barium enema X-ray examinations.

Q: Who are the inventors of US Patent 10,143,656? A: The inventors are Mark vB. Cleveland, Edmund V. Dennett, Jr., and Russell W. Pelham.

Q: What is the expiration date of US Patent 10,143,656? A: The patent is set to expire on August 4, 2037.

Q: Are there any generic versions of Sutab available? A: No, there is currently no therapeutically equivalent version of Sutab available in the United States[2].

Q: How does the Federal Circuit's stance on genus claims affect pharmaceutical patents? A: The Federal Circuit's rigid position on genus claims makes it challenging for innovators to secure broad patent protection without risking invalidation, as claims must meet strict written description and enablement requirements[3].

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 10,143,656

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Patented / Exclusive UseSubmissiondate
Braintree Labs SUTAB magnesium sulfate; potassium chloride; sodium sulfate TABLET;ORAL 213135-001 Nov 10, 2020 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Patented / Exclusive Use>Submissiondate
Showing 1 to 1 of 1 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.